Repligen Corporation ($RGEN) Stock Forecast: Down 5.3% Today

What is Repligen Corporation?

Repligen Corporation (NASDAQ: RGEN) operates in the bioprocessing sector, offering products and services for biologic drug development and production. The company witnessed a notable downturn in the stock market.

Why is Repligen Corporation going down?

RGEN stock is down 5.3% on Apr 8, 2025 17:42

• The announcement of Jacob Johnson as Vice President of Investor Relations elicited mixed reactions from investors, raising uncertainties about the company's trajectory.
• Despite a recent surge in stock price, the absence of optimistic earnings forecast adjustments indicates investor wariness regarding the stock's future performance.
• The decline in RGEN's stock value may be linked to profit-taking actions by investors after a recent price upturn, causing a temporary stock price decrease.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Repligen Appoints Jacob Johnson As Vice President Investor Relations - Repligen ( NASDAQ:RGEN )

WALTHAM, Mass., April 08, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation RGEN today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the ...

https://www.benzinga.com/pressreleases/25/04/g44681699/repligen-appoints-jacob-johnson-as-vice-president-investor-relations

Repligen ( RGEN ) Moves 3.7% Higher: Will This Strength Last?

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

https://www.zacks.com/stock/news/2441594/repligen-rgen-moves-37-higher-will-this-strength-last

Trending Today

EOS ($EOS) Crypto Forecast: Down 8.0% Today

Curve DAO Token ($CRV) Crypto Forecast: Up 17.8% Today

Ethereum ($ETH) Crypto Forecast: Down 5.9% Today

Toncoin ($TON) Crypto Forecast: Down 6.4% Today

XRP ($XRP) Crypto Forecast: Down 5.3% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Down 5.2% Today

Chainlink ($LINK) Crypto Forecast: Down 5.4% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Solana ($SOL) Crypto Forecast: Down 5.4% Today

Memecoin ($MEME) Crypto Forecast: Down 5.6% Today

Repligen Corporation Price History

05.02.2025 - RGEN Stock was up 5.4%

• Repligen acquired the bioprocessing analytics portfolio from 908 Devices, potentially expanding its capabilities in the bioprocessing sector.
• The acquisition likely garnered positive investor sentiment, boosting confidence in Repligen's growth prospects.
• This strategic move could establish Repligen as a significant player in the bioprocessing industry, attracting more investors and contributing to the stock's bullish performance.

14.10.2024 - RGEN Stock was down 5.3%

• Repligen (RGEN) reported strong Q3 earnings and revenue beats, showcasing a robust financial performance.
• Despite the positive earnings report, the stock experienced a bearish movement, possibly due to the company lowering its guidance for 2024 total sales.
• Investors might be reacting to the mixed guidance provided by Repligen, causing a sell-off in the stock despite the positive earnings surprises.
• The market movement could also be influenced by profit-taking activities following the stock's recent strong performance, as investors reassess their positions based on the new sales outlook provided by the company.

20.01.2025 - RGEN Stock was up 9.7%

• Repligen (RGEN) reported strong Q4 earnings, surpassing both EPS and revenue expectations, demonstrating solid financial performance.
• The company provided a strong sales forecast for 2025, displaying confidence in its future growth opportunities.
• The favorable earnings results and positive outlook probably boosted investor confidence, causing a bullish trend in RGEN stock.

20.01.2025 - RGEN Stock was up 11.0%

• Repligen (RGEN) beat Q4 earnings estimates, showing a strong performance in the last quarter.
• The positive earnings surprise of 7.32% and revenue beat of 0.10% likely contributed to the bullish movement in the stock.
• Investors may be optimistic about the company's future prospects based on these strong financial results.
• The market reaction indicates that investors are confident in Repligen's ability to continue its growth trajectory in the bioprocessing sector.

24.01.2025 - RGEN Stock was up 5.0%

• RGEN's Q4 earnings surpassed estimates and revenue aligned with forecasts, demonstrating robust financial results.
• The company's 2025 guidance is optimistic, estimating sales in the range of $685 million-$710 million, reflecting a bullish outlook on future growth.
• Investors responded positively to the strong earnings and projected growth, fueling the upward movement in RGEN stock as confidence in the company's performance and potential strengthened.

18.11.2024 - RGEN Stock was down 5.1%

• The bearish movement in RGEN's stock could be due to profit-taking by investors after a recent 3.2% increase since the last earnings report.
• The publication of the company's 2023 Corporate Sustainability Report may not have had the desired positive impact on the stock price, leading to a sell-off.
• Investors might be cautious about the future outlook of the company, as reflected in the bearish market movement despite the recent earnings report.

29.00.2025 - RGEN Stock was down 5.2%

• Previous rise in Repligen's shares may have resulted in an overestimation of the stock's value, prompting investors to sell off.
• The notable trading volume, combined with the absence of additional positive earnings forecasts, likely influenced profit-taking and a subsequent bearish trend.
• Investors possibly viewed the recent price uptick as unsustainable, triggering a sell-off and contributing to a bearish market trend for Repligen (RGEN) today.

16.00.2025 - RGEN Stock was up 5.2%

• Positive comparisons with other stocks in the same sector, indicating potential undervaluation and attracting investors.
• Increased investor confidence in the company's value proposition and growth prospects, leading to higher demand for the stock.
• Market optimism towards the biotechnology sector as a whole, driving up prices of related stocks like RGEN.

08.03.2025 - RGEN Stock was down 5.3%

• The announcement of Jacob Johnson as Vice President of Investor Relations elicited mixed reactions from investors, raising uncertainties about the company's trajectory.
• Despite a recent surge in stock price, the absence of optimistic earnings forecast adjustments indicates investor wariness regarding the stock's future performance.
• The decline in RGEN's stock value may be linked to profit-taking actions by investors after a recent price upturn, causing a temporary stock price decrease.

18.02.2025 - RGEN Stock was down 6.1%

• Possible profit-taking by investors may have caused a bearish trend for RGEN following a period of bullish activity.
• The positive performance of Ascendis Pharma (ASND) could have drawn investor focus away from RGEN, resulting in a stock sell-off.
• Changes in market sentiment towards biotech stocks may have had a detrimental effect on RGEN's performance.
• It is plausible that specific negative news or developments relating to RGEN have also influenced the bearish movement.

04.02.2025 - RGEN Stock was down 6.4%

• Repligen Corporation's acquisition of the Bioprocessing Analytics Portfolio from 908 Devices might have led to increased investor concerns or uncertainties about the integration process or potential challenges.
• The market may be reacting to the financial implications of the acquisition, with investors potentially perceiving it as overvalued or not immediately accretive to Repligen's bottom line.
• The bearish movement could also be a result of profit-taking by investors who had previously seen significant gains in RGEN's stock price, leading to a temporary downturn in the market sentiment towards the company.

12.01.2025 - RGEN Stock was down 5.0%

• The upcoming financial results announcement may have led to uncertainty and profit-taking among investors, causing a bearish sentiment.
• Investors might be concerned about the company's performance in the fourth quarter of 2024, leading to a sell-off of shares.
• The market may be reacting to potential guidance or outlook provided by Repligen Corporation during the conference call, impacting the stock negatively.
• Traders could be adjusting their positions based on expectations or rumors circulating about the financial health of Repligen Corporation, contributing to the bearish movement in the stock price.